temocillin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Temocillin is a β-lactamase-resistant penicillin introduced by Beecham, marketed by Eumedica Pharmaceuticals as Negaban. It is used primarily for the treatment of multiple drug-resistant, Gram-negative bacteria. It is a 6-methoxy penicillin; it is also a carboxypenicillin.   Wikipedia

Chemistry

  • SMILES: CO[C@]1(NC(=O)C(C(=O)O)c2ccsc2)[C@H]3SC(C)(C)[C@@H](N3C1=O)C(=O)O
  • InChIKey: BVCKFLJARNKCSS-DWPRYXJFSA-N
  • Mol. Mass: 414.46
  • ALogP: 0.52
  • ChEMBL Molecule:
    temocillin  
More Chemistry

Pharmacology

Alternative names

brl 17421 | brl-17421 [as sodium] | disodium 6beta-(2-carboxy-2-thien-3-ylacetamido)-6alpha-methoxypenicillanate | temocillin | temocillin, (2s-(2alpha,5alpha,6alpha))-isomer | temocillin disodium

Organizations (13)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Bacteremia (Phase 3)

Gram-Negative Bacterial Infections (Phase 4)

Infections (Phase 4)

Kidney Diseases (Phase 4)

Liver Diseases (Phase 4)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue